What stage does CentreStone Ventures invest at?

CentreStone Ventures invests at the Seed, Series A stages.

What is CentreStone Ventures's typical check size?

CentreStone Ventures typically writes checks of $182.5K – $1.8M.

What sectors does CentreStone Ventures focus on?

CentreStone Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is CentreStone Ventures located?

CentreStone Ventures is headquartered in Winnipeg, CA.

CentreStone Ventures

Venture capital

Winnipeg · Seed–Series A · 3 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into CentreStone Ventures

Paths you didn't know you had: your email and LinkedIn already hold routes to the CentreStone Ventures team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

CentreStone Ventures backs early-stage life sciences companies developing therapeutics, medical devices, diagnostics and novel drug delivery methods. It targets companies addressing large markets with unmet clinical needs, built on strong intellectual property and a mix of entrepreneurial and technical talent with the potential to lead their markets. Based in Winnipeg at the geographic centre of North America, the firm sources opportunities from research centres across the continent, with particular focus on Western Canada and the U.S. Midwest. Beyond capital, CentreStone partners with scientific entrepreneurs, offering structure, support and guidance to build a foundation for commercial development.

Invests inBiotech Digital Health Healthtech Medical Devices Canada North America United States

Source: firm website, verified Aug 3, 2026.

Leave your own feedback

Stage

Seed–Series A

Check

$182.5K – $1.8M

Winnipeg, Manitoba, CA

Instruments

Equity

Founded

2004

AUM

$18.3M

Tracked investments

IPOs

Team · 3 people

from the firm's website & public directories

Albert D. Friesen· Dr.

Holds a Ph.D. in Protein Chemistry from the University of Manitoba and was the first employee and President of the Winnipeg Rh Institute, overseeing the development of WinRho. He has founded several health industry companies including Novopharm Biotech (now Viventia Biotech), Genesys Pharma, Miraculins, Diamedica and Medicure, and has managed development of numerous pharmaceutical candidates.

adfriesen@centrestoneventures.com

James Kinley· CA

A Chartered Accountant responsible for the financial operations and reporting of GVI and its client companies. He previously managed financial reporting at Manitoba Telecom Services and was an Audit Senior at Ernst & Young.

Marcus Enns· Vice President, Corporate Affairs

Holds a Bachelor of Commerce (Hons.) from the University of Manitoba and joined Genesys Venture Inc. in 2000. He oversees treasury and contract administration, supports fundraising for client companies, and has held executive roles at Miraculins and Kane Biotech.

What they invest in

from 1 of 1 portfolio companies

Biotech ×1Digital Health ×1

HQs:United States×1

Investments · 1 tracked

founders shown can be your intro path

DiaMedica Therapeuticsdiamedica.com in 𝕏NASDAQ: DMAC

DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke.

BiotechDigital HealthMinneapolis, US

David J. Wambeke(Executive Officer)in Lorianne Masuoka(Executive Officer)inRick Pauls(Executive Officer, Director)inScott Kellen(Executive Officer)in Todd Verdoorn(Executive Officer)in Julie Krop(Chief Medical Officer)in

Co-investorsShepherd Ventures

Exits · 1

1 IPOs

DiaMedica TherapeuticsNASDAQ: DMAC

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
DiaMedica Therapeutics	6.0%	$4.00	Dec 2018	$2.8M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

What stage does CentreStone Ventures invest at?: CentreStone Ventures invests at the Seed, Series A stages.
What is CentreStone Ventures's typical check size?: CentreStone Ventures typically writes checks of $182.5K – $1.8M.
What sectors does CentreStone Ventures focus on?: CentreStone Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is CentreStone Ventures located?: CentreStone Ventures is headquartered in Winnipeg, CA.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

$500K – $20M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M